Mevacor Behind-The-Counter Status Is “Not Necessary,” J&J/Merck Says

Behind-the-counter access is "not necessary" if Johnson & Johnson/Merck's lipid-lowering drug Mevacor (lovastatin) were switched from prescription status to OTC, the joint venture maintains